AUG 13, 2026 · PHASE 2 TRIAL
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
ClinicalTrials.gov
A Phase 2 feasibility study with recruitment completed but no clinical outcome results reported; designed to assess trial feasibility and acceptability rather than efficacy.
Reported
Sample size30
Primary outcome measure 1Percentage of eligible versus consented pat…
Primary outcome measure 2Percentage of enrolled patients with comple…